Commensal bacteria: The link between IBS and IBD?

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 14, Issue 5, 2011, Pages 497-503

  Quigley, Eamonn M M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

antibiotics; Crohn's disease; inflammatory bowel disease; irritable bowel syndrome; microbiota; probiotics; ulcerative colitis

Indexed keywords

ANTIBIOTIC AGENT; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; RIFAXIMIN;

BIFIDOBACTERIUM; COMMENSALISM; CROHN DISEASE; ENTERITIS; HUMAN; INTESTINE FLORA; IRRITABLE COLON; LACTOBACILLUS; MOLECULAR INTERACTION; PATHOGENESIS; REVIEW; ULCERATIVE COLITIS;

BACTERIAL PHYSIOLOGICAL PHENOMENA; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; IRRITABLE BOWEL SYNDROME; SYMBIOSIS;

EID: 80051790402     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0b013e328348c033     Document Type: Review

References (66)

1. Hungin AP, Chang L, Locke GR, et al. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther 2005;21:1365-1375. (Pubitemid 40813683)
2. Quigley EMM, Bergmann J-F, Bytzer P, et al. An evidence-based approach to the management of irritable bowel syndrome in Europe. Eur J Gastroenterol Hepatol 2007;19(Suppl 1):S1-S37.
3. Gwee KA, Bak YT, Ghoshal UC, et al. Asian consensus on irritable bowel syndrome. J Gastroenterol Hepatol 2010;25:1189-1205. An important survey of the prevalence, presenting features and management of IBS in Asia which reveals some interesting deviations from Western experience in terms of demographics and symptomatology.
4. Bernstein CN, Wajda A, Svenson LW, et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006;101:1559-1568. (Pubitemid 43980630)
5. Van Limbergen J, Wilson DC, Satsangi J. The genetics of Crohn's disease. Annu Rev Genomics Hum Genet 2009;10:89-116.
6. McLaughlin SD, Clark SK, Tekkis PP, et al. The bacterial pathogenesis and treatment of pouchitis. Ther Adv Gastroenterol 2010;3:335-348.
7. Thabane M, Marshall JK. Postinfectious irritable bowel syndrome. World J Gastroenterol 2009;15:3591-3596.
8. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009;136:1979-1988.
9. Villani AC, Lemire M, Thabane M, et al. Genetic risk factors for postinfectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010;138:1502-1513. Identifies genetic factors that seem to predispose to PI-IBS and link its development to deficits in the epithelial barrier and the host immune response.
10. Craig OF, Quigley EMM. Bacteria, genetics and irritable bowel syndrome (IBS). Expert Rev Gastroenterol 2010;4:271-276.
11. Clayton EM, Rea MC, Shanahan F, et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol 2009;104:1162-1169.
12. Gradel KO, Nielsen HL, Schønheyder HC, et al. Increased short-and longterm risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. Gastroenterology 2009;137:495-501.
13. Quigley EMM. Do patients with functional gastrointestinal disorders have an altered flora? Ther Adv Gastroenterol 2009;2(Suppl 1):S23-S30.
14. Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010;7:163-173.
15. Brint EK, MacSharry J, Fanning A, et al. Differential expression of Toll-like receptors (TLRs) in patients with irritable bowel syndrome. Am J Gastroenterol 2011;106:329-336. By demonstrating up-regulation of genes encoding forTLR-4, as well as increased expression of TLR-4 in the colonic epithelium, provides the much-needed link between Gram-negative bacteria and IBS, suggesting that these organisms may be responsible for the enhanced inflammatory response seen in IBS.
16. Langhorst J, Junge A, Rueffer A, et al. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol 2009;104:404-410.
17. McKernan DP, Gaszner G, Quigley EM, et al. Altered peripheral toll-like receptor responses in the irritable bowel syndrome. Aliment Pharmacol Ther 2011;33:1045-1052.
18. Rhee SH. Basic and translational understandings of microbial recognition by toll-like receptors in the intestine. J Neurogastroenterol Motil 2011;17:28-34.
19. Quigley EM. The enteric microbiota in the pathogenesis and management of constipation. Best Pract Res Clin Gastroenterol 2011;25:119-126. An up-to-date review of the status of antibacterial, microbiota-modifying and antiinflammatory approaches in constipation.
20. Quigley EM. Germs, gas and the gut; the evolving role of the enteric flora in IBS. Am J Gastroenterol 2006;101:334-335. (Pubitemid 43381676)
21. Tana C, Umesaki Y, Imaoka A, et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2010;22:512-519.
22. Ponnusamy K, Choi JN, Kim J, et al. Microbial community and metabolomic comparison of irritable bowel syndrome faeces. J Med Microbiol 2011 [Epub ahead of print].
23. Carroll IM, Chang YH, Park J, et al. Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Gut Pathog 2010;2:19.
24. Noor SO, Ridgway K, Scovell L, et al. Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota. BMC Gastroenterol 2010;10:134.
25. Kerckhoffs AP, Ben-Amor K, Samsom M, et al. Molecular analysis of faecal and duodenal samples reveals significantly higher prevalence and numbers of Pseudomonas aeruginosa in irritable bowel syndrome. J Med Microbiol 2011;60:236-245.
26. Malinen E, Krogius-Kurikka L, Lyra A, et al. Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome. World J Gastroenterol 2010;16:4532-4540.
27. Krogius-Kurikka L, Lyra A, Malinen E, et al. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol 2009;9:95.
28. Lyra A, Rinttila T, Nikkila J, et al. Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. World J Gastroenterol 2009;15:5936-5945.
29. Codling C, O'Mahony L, Shanahan F, et al. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig DisSci 2010;55:392-397.
30. Kerckhoffs AP, Samsom M, van der Rest ME, et al. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 2009;15:2887-2892.
31. Lee KJ, Tack J. Altered intestinal microbiota in irritable bowel syndrome. Neurogastroenterol Motil 2010;22:493-498.
32. Cremon C, Carini G, De Giorgio R, et al. Intestinal dysbiosis in irritable bowel syndrome: etiological factor or epiphenomenon? Expert Rev Mol Diagn 2010;10:389-393. A critical review of the microbiota in IBS.
33. Quigley EM, Abu-Shanab A. Small intestinal bacterial overgrowth. Infect Dis Clin North Am 2010;24:943-959.
34. Yu D, Cheeseman F, Vanner S. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut 2011;60:334-340.
35. Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009;7:1279-1286.
36. Spiegel BM. Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective. Clin Gastroenterol Hepatol 2011 [Epub ahead of print]. A thoughtful, insightful and critical review of the role of SIBO in IBS.
37. Sartor RB. Microbial influences in inflammatory bowel disease. Gastroenterology 2008;134:577-594. (Pubitemid 351173057)
38. Sartor RB. Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis. Gastroenterology 2010;139:181 6-1819. A concise review of interactions between the microbiota, genetics and the environment in Crohn's disease.
39. Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 2011;60:631-637. One of the largest studies, to date, of the microbiota in Crohn's disease which compared Crohn's patients, not just with healthy controls, but also with unaffected relatives and, by revealing different patterns of dysbiosis in the patients and their unaffected relatives, suggests a role for the microbiota independent of diet and genetic background in this form of IBD.
40. Willing BP, Dicksved J, Halfvarson J, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 2010;139:1844-1854. A detailed examination of the microbiota in Crohn's, ulcerative colitis and control individuals demonstrating, not only difference between Crohn's and ulcerative colitis and controls, but also differences between those with ileal and colonic Crohn's disease.
41. Frank DN, Robertson CE, Hamm CM, et al. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2011;17:179-184.
42. Walker AW, Sanderson JD, Churcher C, et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and noninflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol 2011;11:7. Raises the possibility that microbial changes in IBD may be the consequence rather than the cause of the inflammatory process.
43. Sartor RB. Key questions to guide a better understanding of host-commensal microbiota interactions in intestinal inflammation. Mucosal Immunol 2011;4:127-132. Raises many of the issues and challenges that will need to be addressed in future studies of the role of the microbiota in inflammatory disease processes in the gastrointestinal tract.
44. Willing B, Halfvarson J, Dicksved J, et al. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. Inflamm Bowel Dis 2009;15:653-660.
45. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an antiinflammatory commensal bacterium identified by gut microbiota analysis of Crohn's disease patients. Proc Natl Acad Sci USA 2008;105:16731-16736.
46. Kang S, Denman SE, Morrison M, et al. Dysbiosis of fecal microbiota in Crohn's disease patients as revealed by a custom phylogenetic microarray. Inflamm Bowel Dis 2010;16:2034-2042.
47. Ng SC, Benjamin JL, McCarthy NE, et al. Relationship between human intestinal dendritic cells, gut microbiota, and disease activity in Crohn's disease. Inflamm Bowel Dis 2010 [Epub ahead of print].
48. Tannock GW. The bowel microbiota and inflammatory bowel diseases. Int J Inflamm 2010;2010:954051. A thorough review of the pitfalls that have beset and the challenges that lie ahead for studies of the microbiota in IBD; many of these issues are also relevant to IBS.
49. Keohane J, O'Mahony C, O'Mahony L, et al. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol 2010;105:1789-1884.
50. Burgmann T, Clara I, Graff L, et al. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis: how much is irritable bowel syndrome? Clin Gastroenterol Hepatol 2006;4:614-620.
51. Lembo A, Zakko SF, Ferreira NL, et al. Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short-term treatment leading to long term sustained response. Gastroenterology 2008;134:A-545.
52. Ringel Y, Zakko SF, Ferreira NL, et al. Predictors of clinical response from a phase 2 multicenter efficacy trial using rifaximin, a gut-selective, nonabsorbed antibiotic for the treatment of diarrhea-associated irritable bowel syndrome. Gastroenterology 2008;134:A-550.
53. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. New Engl J Med 2011;364:22-32.
54. Quigley EM. Therapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, probiotics, synbiotics, anti-inflammatory therapies. Gastroenterol Clin North Am 2011;40:207-222.
55. Quigley EM. Prebiotics and probiotics; modifying and mining the microbiota. Pharmacol Res 2010;61:213-218.
56. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut 2010;59:325-332.
57. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009;104:1033-1049.
58. Silk DBA, Davis A, Vulevic J, et al. Clinical trial: the effects of a transgalactooligosaccheride on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 2009;29:508-518.
59. Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011;106:661-673. A detailed, high-quality systematic review and meta-analysis which does reveal evidence of efficacy for antibiotics in the induction of remission in both Crohn's disease and ulcerative colitis; however, the use of abroad range of antibiotics makes it difficult to translate these findings into a clinical recommendation. More trials needed!
60. Prantera C, Scribano ML. Antibiotics and probiotics in inflammatory bowel disease: why, when, and how. Curr Opin Gastroenterol 2009;25:329-333.
61. Doherty G, Bennett G, Patil S, et al. Interventions for prevention of postoperative recurrence of Crohn's disease. Cochrane Database Syst Rev 2009;CD006873.
62. Feller M, Huwiler K, Schoepfer A, et al. Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. Clin Infect Dis 2010;50:473-480.
63. Holubar SD, Cima RR, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anatomises for chronic ulcerative colitis. Cochrane Database Syst Rev 2010;CD001176.
64. Shanahan F, Collins SM. Pharmabiotic manipulation of the microbiota in gastrointestinal disorders, from rationale to reality. Gastroenterol Clin North Am 2010;39:721-726. A comprehensive and critical review of the current status of 'pharmabiotics' in the management of gastrointestinal disorders, including IBS and IBD.
65. Ewaschuk JB, Tejpar QZ, Soo I, et al. The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease. Curr Gastroenterol Rep 2006;8:486-498. (Pubitemid 46017161)
66. Benjamin JL, Hedin CR, Koutsoumpas A, et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut 2011 [Epub ahead of print].